More Images
EMERYVILLE, Calif.—NovaBay Pharmaceuticals Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova, said Monday that it has reached an exclusive 90-day agreement with NuSight Medical to distribute the NuLids System for treatment of blepharitis and dry eye in six of NovaBay’s top-performing territories. The NuLids System is a hand-held, cordless device that safely and effectively removes accumulated scurf from eyelashes and eyelids, while stimulating meibomian gland production in dry eye and blepharitis patients, according to the announcement.

The NuLids System is available through eyecare professionals for home use by the patient. NovaBay said it expects to begin selling the NuLids System at the beginning of November in the greater mid-Atlantic region.

“The NuLids System is highly complementary to Avenova and, in fact, we believe that anyone using this product should also be using Avenova to treat both the symptoms and the underlying cause of blepharitis and bacterial dry eye,” NovaBay chief executive officer Justin Hall said in the announcement. “We further believe the NuLids System will elevate our sales calls with ophthalmologists and optometrists and make our salespeople more productive. The NuLids System is available through eyecare professionals, which supports our buy-and-sell sales channel for Avenova.

“We are delighted to be working with NovaBay, which has a salesforce that is dedicated to the treatment of dry eye and has established relationships with eyecare specialists,” Robert Foster, NuSight Medical’s chief executive officer, said. “This agreement expands upon our existing professional dealer network with a highly credible distribution partner in a large geographic territory that had previously been underserved.”

According to Foster, one-year patient survey data has shown that 96 percent of patients surveyed after a 30-day trial reported being either “satisfied” or “very satisfied” with NuLids.

The NuLids System requires just one minute each day to treat both eyes, according to the announcement. Clinical results show a significant reduction in the signs and symptoms associated with dry eye.